WaveMan
WaveMan · Company
SCLX · Scilex Holding Co
> Search tickers & screens ⌘K
LIVE
← All companies

SCLX Scilex (SCLX) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001820190
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
23
13F, latest reported quarter

Scilex insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Scilex Holding Co in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Scilex Holding Co
SELL
2025-12-30 SEC
9,657,300
$5.2M
-69.3%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Dec 29, 2025.
  • The trade is 4.0% of the 244,445,260 shares held after it.
  • No other insider sold within 30 days.
  • 23 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Scilex Holding Co sold about $5.2M of SCLX on Dec 30, 2025, the largest insider sale at the company on our record; 23 funds added in the latest 13F quarter.
Scilex Holding Co
SELL
2025-12-30 SECtraded 2025-12-29
7,310,984
$4.8M
-69.3%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Dec 26, 2025.
  • The trade is 2.9% of the 254,102,560 shares held after it.
  • No other insider sold within 30 days.
  • 23 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Scilex Holding Co sold about $4.8M of SCLX on Dec 29, 2025, the largest insider sale at the company on our record; 23 funds added in the latest 13F quarter.
Scilex Holding Co
SELL
2025-12-30 SECtraded 2025-12-26
3,689,016
$2.8M
-69.3%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 1.4% of the 261,413,544 shares held after it.
  • No other insider sold within 30 days.
  • 23 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Scilex Holding Co sold about $2.8M of SCLX on Dec 26, 2025, the largest insider sale at the company on our record; 23 funds added in the latest 13F quarter.
SHAH JAISIM
See Remarks
BUY
2024-12-18 SEC
30,000
$13.8K
-75.7%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 buys), the last on Oct 29, 2024.
  • -5.2% median (-5.1% mean) 90-day return after 4 previous buys.
  • The trade is 21.5% of the 139,333 shares held after it.
  • No other insider bought within 30 days.
  • 23 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks SHAH JAISIM bought about $13.8K of SCLX on Dec 18, 2024; 23 funds added in the latest 13F quarter.
Ji Henry
Executive Chairperson
BUY
2024-10-31 SEC
8,888
$8.4K
-89.0%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Oct 17, 2024.
  • -7.6% median (-7.6% mean) 90-day return after 2 previous buys.
  • The trade is 2.8% of the 320,161 shares held after it.
  • 6 other insiders bought within 30 days.
  • 23 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Executive Chairperson Ji Henry bought about $8.4K of SCLX on Oct 31, 2024; 6 other insiders bought within 30 days and 23 funds added in the latest 13F quarter.
19 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 14 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
23 funds bought in last quarter
below 66% of Pharma & Biotech
Revenue
-46.5% year over year
below 79% of Pharma & Biotech
Margin
-1236.4% net margin
below 88% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
2.6% of the float short (float per yahoo 2026-10-27) · 2.6 days to cover · settled 2026-10-15
below 67% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch SCLX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-74.4%12M
-74%-31%+11%+54%2025-102025-122026-022026-042026-062026-082026-10 2025-12-30 · Scilex Holding Co sold $5.2M2025-12-29 · Scilex Holding Co sold $4.8M2025-12-26 · Scilex Holding Co sold $2.8M
Insider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns SCLX: institutional holders (13F)

13F holdings, latest reported quarter
VANGUARD CAPITAL MANAGEMENT LLC
301,292 sh
$2.4M
BlackRock, Inc.
109,417 sh
$853.5K
VANGUARD FIDUCIARY TRUST CO
45,822 sh
$357.4K
JACOBS LEVY EQUITY MANAGEMENT, INC
41,163 sh
$321.1K
STATE STREET CORP
35,376 sh
$275.9K

Congress trades in SCLX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

SCLX planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

SCLX mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
iShares Micro-Cap ETF
$186.7K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$13.1K position · as of 2026-06-30
0.0%
T. Rowe Price Extended Equity Market Index Fund
$53.8K position · as of 2026-06-30
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$594.6K position · as of 2026-06-30
0.0%
MetLife Russell 2000 Index Portfolio
$4.9K position · as of 2026-06-30
0.0%
SIIT EXTENDED MARKET INDEX FUND
$3.1K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 23 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

SCLX financials

Revenue growth
-46.5%
XBRL, annual
Net margin
-1236.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$31.6M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-1,470%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Cash flow to debt
-0.21x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Return on equity
n/a
average equity is zero or negative
Return on assets
-275.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
n/a
capital employed is zero or negative
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$100.0M
market value at close 2026-10-26 on 2026-08-10 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$30.3M$56.6M$46.7M$38.0M
Gross profit$125.8M$167.4Mn/an/a
Operating income-$346.0M-$83.4M-$105.4M-$50.6M
Net income-$374.1M-$72.8M-$114.3M-$23.4M
EPS (diluted)-36.48-8.05-1.28-0.17
Operating cash flow$3.8M$19.3M-$20.7M-$21.3M
Cash$5.0M$3.3M$3.9M$2.2M
Long-term debt$22.5M$845.0K$17.0M$0
Dividends paidn/a$8.7M$8.7Mn/a
SEC XBRL, fiscal years, as known on 2026-10-28

SCLX Stock Sonar score 4/7 axes

Find similar shapesCompare

SCLX ranks highest on financial health (64th percentile) and risk and compliance (45th), and lowest on growth (21st), among Pharma & Biotech peers.

Financial health
64
Inputs
  • Debt to equityequity is zero or negative, the ratio has no meaning
  • Cash flow to debt-0.21x · 64 pct, sector of 371
Growth
21
Inputs
  • Revenue growth, YoY-46.5% · 21 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Institutional and government
34
Inputs
  • Funds adding, latest quarter23 · 34 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
45
Inputs
  • Short interest, % of float+2.6% · 69 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+18.4% · 21 pct, sector of 511
3 not measured: Profitability, Insider conviction, US patents
  • Profitability needs 2 of 4 inputs, 1 present: average equity is zero or negative; capital employed is zero or negative; tax provision or pre-tax income not filed for the four quarters
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies